Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

Interest Coverage 1.41
NTII's Interest Coverage is ranked lower than
99.99% of the 364 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NTII: 1.41 )
Ranked among companies with meaningful Interest Coverage only.
NTII' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 1.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

» NTII's 10-Y Financials

Financials (Next Earnings Date: 0)

Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with NTII

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
A biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions.

Neurobiological Technologies, Inc. is focused on developing novel, first-in-class treatments for central nervous system conditions and other serious unmet medical needs. The company's most advanced product candidate, Viprinex'TM', is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Stroke is one of the most prevalent, debilitating and costly diseases in the world, and there are few acceptable treatment options. Viprinex is a fibrinogen-reducing agent that is designed to expand the treatment window from three hours to six hours. The company has the right to receive royalty payments from the sales of Namenda'R' 'memantine HCL', an approved drug marketed for Alzheimer's disease and potential milestone and royalty payments from the development of XERECEPT, an investigational drug which is in Phase 3 clinical trials for the treatment of swelling associated with cerebral tumors. Additionally, NTI's earlier stage pipeline includes rights to two proteins in preclinical development for the treatment of Alzheimer's disease and Huntington's disease.



Valuation & Return


More Statistics

Revenue (TTM) (Mil) $26.35
EPS (TTM) $ 0.12
Short Percentage of Float0.34%
52-Week Range $0.01 - 0.04
Shares Outstanding (Mil)27.02

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)